Ragibe Gulsah Dilaver

Ragibe Gulsah Dilaver

Auto-generated profile, based on publicly available information

Ragibe Gulsah Dilaver

Department of Medicine, Division of Nephrology and Hypertension Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Physiological Reports
Verified
Journal Article
Open access
RDR. Gulsah Dilaver
R. Gulsah Dilaver
MDMert Demirci
Mert Demirci
RCRachelle Crescenzi
Rachelle Crescenzi
MPMichael Pridmore
Michael Pridmore
LELale A. Ertuglu
Lale A. Ertuglu
JGJorge L. Gamboa
Jorge L. Gamboa
Sarcopenia is common in advanced chronic kidney disease (CKD), contributing to poor outcomes. Intermuscular adipose tissue (IMAT) may worsen muscle function through metabolic and inflammatory pathways. We conducted a cross‐sectional study comparing maintenance hemodialysis (MHD) patients and controls to assess IMAT and its associations. IMAT was measured via calf muscle MRI, and body composition (BMI, fat mass index), metabolic markers (hs‐CRP, TNF‐α, IL‐6, insulin resistance), and circulating cell‐free mitochondrial DNA (ccf‐mtDNA) were assessed. Muscle function was evaluated with handgrip strength. IMAT differences between groups were tested using inverse propensity weighting. We analyzed 25 MHD patients and 23 controls. Median age was 53 years, BMI 30.4 kg/m2, 83% were male, and 56% were African American. Baseline characteristics were similar between groups, except for race. MHD patients had higher IMAT (p < 0.01) and elevated TNF‐α, IL‐6, and hs‐CRP (p < 0.01). IMAT was positively correlated with IL‐6 in MHD patients and with TNF‐α in controls. Handgrip strength was inversely correlated with IMAT in the full cohort (p < 0.01). Our findings highlight the role of IMAT in inflammation and functional decline in CKD, suggesting its potential as a therapeutic target.

30 April 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MDMert Demirci
Mert Demirci
RDR. Gulsah Dilaver
R. Gulsah Dilaver
BRBaback Roshanravan
Baback Roshanravan
TITalat Alp Ikizler
Talat Alp Ikizler
JGJorge L. Gamboa
Jorge L. Gamboa
Patients with CKD often experience loss of muscle mass, altered muscle function, and low physical functionality, all of which contribute to increased mortality and morbidity. Mitochondrial dysfunction emerges early in the progression of CKD and may play a central role in physical dysfunction. Factors such as uremia, systemic inflammation, oxidative stress, and inappropriate activation of the renin-angiotensin-aldosterone system may play a role on mitochondrial dysfunction. On the other hand, the accumulation of ectopic adipose tissue in skeletal muscle, also known as intermuscular adipose tissue (IMAT), is a newly recognized factor in muscle function and physical performance. IMAT is a marker of muscle quality, adversely affecting local muscle function, and is associated with insulin resistance and systemic inflammation, conditions commonly observed in CKD. Nevertheless, the exact composition of IMAT and its relationship with mitochondria and muscle energetics in CKD is not fully understood. Evaluating the relationship between IMAT accumulation and mitochondrial dysfunction in CKD may unveil potential interventions to improve physical function and the quality of life of patients with CKD.

2 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
RDR. Gulsah Dilaver
R. Gulsah Dilaver
MDMert Demirci
Mert Demirci
RCRachelle Crescenzi
Rachelle Crescenzi
MPMichael Pridmore
Michael Pridmore
LELale A. Ertuglu
Lale A. Ertuglu
JGJorge L. Gamboa
Jorge L. Gamboa
Background and Aims Sarcopenia, defined as a loss in muscle mass and strength, is common in patients with advanced chronic kidney disease (CKD), leading to poor outcomes. Intermuscular adipose tissue (IMAT) accumulation is associated with metabolic and functional abnormalities in chronic disease conditions. This study assesses IMAT in maintenance hemodialysis (MHD) patients and its association with metabolic markers and physical performance. Methods and Results We performed a cross-sectional study comparing MHD patients with controls. IMAT accumulation was measured by analyzing the fat-to-muscle ratio of the calf muscles through Magnetic Resonance Imaging (MRI) scans. Body composition and metabolic markers were assessed (hs-CRP, TNF-α, IL-6, and insulin resistance). Circulating cell-free mitochondrial DNA (ccf-mtDNA) was quantified using qRT-PCR. Muscle function was evaluated with handgrip strength. Inverse propensity weighted (IPW) method was used to test the difference between IMAT levels of the groups. Twenty-five MHD patients and 23 controls were analyzed. The MHD group had higher IMAT accumulation than controls (p < 0.01). IMAT was positively correlated with Body Mass Index (BMI) and fat mass index (FMI) in controls. MHD patients exhibited elevated TNF-α, IL-6, and hs-CRP levels (p < 0.01). Positive correlations were found between IMAT and IL-6 in MHD patients and between IMAT and TNF-α in controls. Handgrip strength was negatively correlated with IMAT in the entire cohort (p <0.01). Conclusion Our findings highlight the potential role of IMAT in muscle catabolism and functional decline in advanced CKD. Targeting IMAT could be a valuable strategy for improving health outcomes in this population.

20 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
RDRagibe Gulsah Dilaver
Ragibe Gulsah Dilaver
RARengin Elsurer Afsar
Rengin Elsurer Afsar
RCRachelle Crescenzi
Rachelle Crescenzi
JGJorge Gamboa
Jorge Gamboa
TITalat Alp Ikizler
Talat Alp Ikizler
Introduction: Patients with chronic kidney disease (CKD) often exhibit ectopic fat accumulation, including intermuscular adipose tissue (IMAT), which is associated with metabolic and muscular dysfunctions. This study aimed to evaluate the effects of dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on reducing IMAT and improving metabolic and physical functions in patients with CKD stage 3-4. Methods: Seven patients were recruited between April 2022 and November 2023. A 12-week dulaglutide (1.5 mg/wk) intervention was conducted with pre-and post-treatment assessments, including magnetic resonance imaging (MRI) for the IMAT evaluation and systemic physical performance battery test (SPPB) for physical performance evaluation. Their body mass indexes (BMI) were calculated and blood samples were analyzed for inflammatory and metabolic markers, including high sensitive C-reactive protein (Hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), glucose, insulin resistance (IR), total cholesterol, triglyceride, adiponectin, leptin, and leptin-adiponectin ratio (LAR) before and after treatment. Paired t-tests and Mann-Whitney U tests were used for statistical analysis, with significance set at p < 0.05. Results: Out of 58 assessed patients with CKD stage 3-4, 7 were enrolled, with 5 completing the full 12-week dulaglutide treatment. The total 7 people had a mean age of 59 years, mean BMI of 31.4 kg/m², and baseline eGFR of 31.7 mL/min/1.73m². IMAT decreased in 4 patients and increased in 3 patients, with no statistically significant changes overall (p = 0.69). The quadriceps muscle cross-sectional area (CSA) also showed no significant difference (p = 0.73). BMI and serum leptin levels significantly decreased after treatment (p < 0.05), while other inflammatory and metabolic markers, and physical performance scores showed no significant changes. No serious adverse events were reported. Conclusions: This study examined the effects of a 12-week dulaglutide treatment on IMAT accumulation in patients with CKD stage 3-4. While BMI significantly decreased, changes in IMAT were modest and not statistically significant, with potential but unproven clinical and metabolic benefits. Many metabolic and inflammatory markers improved, though not statistically significantly, and physical performance remained unchanged. Muscle CSA and function were maintained, which may alleviate concerns about potential GLP-1RA-induced muscle loss. Dulaglutide was well-tolerated, with minimal side effects. The small sample size and short duration highlight the need for further research. Trial Registration: Name of the Registry : ClinicalTrials.gov Trial Registration Number : NCT05254418 Date of Registration : 2022-02-01

23 August 2024 in Journal of Renal Nutrition
Verified
Journal Article
Open access
RDRagibe Gulsah Dilaver
Ragibe Gulsah Dilaver
AGAndrew Guide
Andrew Guide
RGRobert Greevy
Robert Greevy
TITalat Alp Ikizler
Talat Alp Ikizler
ABAyse Zeynep Bal
Ayse Zeynep Bal
Anorexia is common in patients with chronic kidney disease (CKD) and could lead to protein energy wasting (PEW). An altered sense of smell, a reflection of olfactory dysfunction, is a potential mechanism that exacerbates the impact of anorexia on PEW. In this study, we examined the extent of the altered sense of smell and its association with PEW in patients with moderate to advanced CKD. We studied 139 individuals (34 healthy subjects - controls, 50 patients with stage 3-4 CKD, 55 patients on maintenance hemodialysis - MHD) using the odor identification test (Sniffin' Sticks odor screening test containing 12 different smells). The odor identification test was scored as either correct or incorrect, and each participant's total odor score was calculated. Malnutrition Inflammation Score (MIS) was used to assess PEW. Patients with CKD had higher C-reactive protein (CRP) and lower serum albumin concentrations compared to healthy individuals. Total odor scores were different between groups, with controls having the highest scores and MHD patients having the lowest scores. A similar difference was observed in MIS, MHD patients displaying the worst nutritional score (p ≤ 0.001). The number of participants with severe olfactory dysfunction (≤ 6 correct answers) was significantly higher in the CKD and MHD groups compared to the controls (p ≤ 0.01). There was an inverse trend between the total odor score and the MIS score for the study population. However, this relationship was not statistically significant (r = -0.124, p = 0.21). This cross-sectional study suggests that olfactory dysfunction, as assessed by the odor identification test, is altered in patients with advanced CKD, most notably in ones on MHD. Although the diminished sense of smell was observed alongside development of PEW, we explicitly noted that there is no statistically significant correlation.